NICE backs use of blood cancer drug Gazyvaro within the CDF July 27, 2017

26 July 2017

UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) final draft guidance recommends the use of blood cancer drug Gazyvaro (obinutuzumab) with bendamustine for use within the Cancer Drugs Fund (CDF).

The drug combination from Swiss pharma giant Roche (ROG: SIX), also known as O-Benda+O, is used to treat some people with follicular lymphoma, a rare type of non-Hodgkin lymphoma. It is used to treat these people if their disease has not responded to or has progressed during or up to six months after treatment with rituximab, either or its own or in combination with chemotherapy.

The NICE appraisal committee concluded that O-Benda+O is clinically effective, but were uncertain of its overall survival gain. Therefore, the committee recommended its use in the CDF while further evidence is collected.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK